Sandoz Group Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Sandoz Group de 24% y 5.6% por año respectivamente. Se prevé que el BPA crezca en un 23.5% al año. Se espera que la rentabilidad financiera sea de 17.5% en 3 años.
Información clave
24.0%
Tasa de crecimiento de los beneficios
23.48%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 12.0% |
| Tasa de crecimiento de los ingresos | 5.6% |
| Rentabilidad financiera futura | 17.46% |
| Cobertura de analistas | Good |
| Última actualización | 11 Sep 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Sep 03
SDZ: Biosimilar Expansion And Margin Shift Will Guide Future P/E Profile
Analysts have lifted the fair value estimate for Sandoz Group, with the implied price target moving higher by CHF 1.74 to CHF 72.48. They cite updated assumptions on discount rate, revenue growth, profit margins and future P/E that align with recent Street research pointing to a CHF 80 target.
Actualización de narrativa • Aug 16
SDZ: Brazil Diabetes Entry And Legal Settlements Will Still Restrain Earnings Multiple
Analysts have lifted the Sandoz Group price target by CHF 5 to CHF 80, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Sandoz Group Sandoz Group agreed US settlements totaling US$478.5 million related to generic drug pricing investigations, reducing a long running source of legal uncertainty.Actualización de narrativa • Aug 02
SDZ: Upgraded GLP-1 Ambitions Will Still Face Earnings And Multiple Pressure
Analysts have trimmed their price target for Sandoz Group to around CHF53 from about CHF54, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that align with the recent upgrade highlighted in Street research. What’s in the News for Sandoz Group Sandoz Group received marketing authorisation in Brazil for Owozy, a semaglutide treatment for type-2 diabetes.Actualización de narrativa • Jul 10
SDZ: Elevated Biosimilar Ambitions Will Face Fragile Earnings And Multiple Compression Risk
Analysts have nudged their price expectations higher for Sandoz Group, with the updated fair value estimate moving from about CHF 47.30 to roughly CHF 54.20, as they adjust assumptions around revenue growth, profit margins and the stock's future P/E in light of recent mixed target changes and an upgrade in Street research. Analyst Commentary Street research on Sandoz Group has been mixed, with some firms lifting their targets and others trimming expectations.Actualización de narrativa • Jun 26
SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E
The analyst price target for Sandoz Group has been revised to CHF 70.74, reflecting updated views on fair value, revenue growth, profit margins, and future P/E after a mix of recent target cuts, target hikes, and an upgrade from major banks. Analyst Commentary Recent Street research on Sandoz Group shows a mix of optimism and restraint, with major banks adjusting their views on valuation, execution, and growth expectations.Artículo de análisis • Jun 19
Sandoz Group (SWX:SDZ) Stock Could Be 2% Overvalued After Ljubljana Biosimilar Centre Launch
Sandoz Group (SWX:SDZ) has opened a new biosimilar development centre in Ljubljana, Slovenia, a fully digitally integrated US$99 million facility that expands its in house capabilities across drug substance and drug product development. See our latest analysis for Sandoz Group. Set against this investment in Ljubljana, Sandoz Group’s 1 day share price return declined 1.60% to CHF67.68, while its year to date share price return of 18.28% and 1 year total shareholder return of 57.12% suggest...Actualización de narrativa • Jun 11
SDZ: Elevated Biosimilar Ambitions Will Face Tighter Execution And Margin Scrutiny
Analysts have lifted their CHF price target on Sandoz Group to reflect a fair value shift from about CHF 45.23 to roughly CHF 47.30, citing updated assumptions on revenue growth, margins, and future P/E expectations shaped by recent upgrades, downgrades, and target changes across the Street. Analyst Commentary Recent Street research on Sandoz Group has been mixed, with some firms expressing confidence through upgrades and higher price targets, while others are more cautious.Actualización de narrativa • May 28
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have adjusted the Sandoz Group price target slightly higher, with the updated fair value estimate moving from about CHF 66.01 to CHF 66.36 as they factor in modestly different assumptions for growth, margins and future P/E, following a mix of recent upgrades, initiations and target changes across the Street. Analyst Commentary Recent research on Sandoz Group reflects a mix of optimism and caution, with several firms adjusting ratings and price targets in different directions.Actualización de narrativa • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.Actualización de narrativa • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Actualización de narrativa • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Actualización de narrativa • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.Actualización de narrativa • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.Actualización de narrativa • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.Actualización de narrativa • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.Actualización de narrativa • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.Actualización de narrativa • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.Actualización de narrativa • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.Actualización de narrativa • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.Actualización de narrativa • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.Actualización de narrativa • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.Actualización de narrativa • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.Actualización de narrativa • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.Nueva narrativa • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 13,391 | 1,901 | 1,363 | 2,227 | 13 |
| 12/31/2027 | 12,762 | 1,661 | 1,111 | 1,973 | 14 |
| 12/31/2026 | 12,098 | 1,133 | 530 | 1,480 | 13 |
| 6/30/2026 | 11,676 | 646 | 966 | 1,942 | N/A |
| 3/31/2026 | 11,417 | 780 | 901 | 1,768 | N/A |
| 12/31/2025 | 11,157 | 914 | 836 | 1,594 | N/A |
| 9/30/2025 | 10,872 | 571 | 548 | 1,272 | N/A |
| 6/30/2025 | 10,587 | 227 | 259 | 950 | N/A |
| 3/31/2025 | 10,486 | 114 | 168 | 803 | N/A |
| 12/31/2024 | 10,384 | N/A | 76 | 656 | N/A |
| 9/30/2024 | 10,248 | -4 | -28 | 581 | N/A |
| 6/30/2024 | 10,111 | -8 | -133 | 506 | N/A |
| 3/31/2024 | 10,045 | 35 | -195 | 434 | N/A |
| 12/31/2023 | 9,979 | 77 | -258 | 362 | N/A |
| 9/30/2023 | 9,770 | 345 | 136 | 664 | N/A |
| 6/30/2023 | 9,561 | 613 | 530 | 966 | N/A |
| 3/31/2023 | 9,434 | 731 | 679 | 1,095 | N/A |
| 12/31/2022 | 9,306 | 848 | 828 | 1,223 | N/A |
| 12/31/2021 | 9,678 | 908 | 1,000 | 1,354 | N/A |
| 12/31/2020 | 9,658 | 462 | 813 | 1,098 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (24% al año) de SDZ es superior a la tasa de ahorro (0.6%).
Beneficios vs. Mercado: Se prevé que los beneficios (24% al año) de SDZ crezcan más rápidamente que el mercado Swiss (12.2% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de SDZ crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (5.6% al año) de SDZ crezcan más rápidamente que los del mercado Swiss (5.2% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 5.6% al año) de SDZ crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de SDZ sea baja dentro de 3 años (17.5%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 19:21 |
| Precio de las acciones al final del día | 2026/09/14 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Sandoz Group AG está cubierta por 37 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |